Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection

被引:109
作者
Bahrami, G [1 ]
Mohammadi, B
Mirzaeei, S
Kiani, A
机构
[1] Karmanshah Univ Med Sci, Sch Med, Med Biol Res Ctr, Kermanshah 6714869914, Iran
[2] Kermanshah Univ Med Sci, Sch Pharm, Kermanshah, Iran
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2005年 / 826卷 / 1-2期
关键词
chromatography; HPLC; atorvastatin; serum; bioequivalence study; statins;
D O I
10.1016/j.jchromb.2005.08.008
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A rapid and sensitive high-performance liquid chromatographic method was validated and described for determination of atorvastatin in human serum. Following liquid-liquid extraction of the drug and an internal standard (sodium diclofenac), chromatographic separation was accomplished using C18 analytical column with a mobile phase consisting of sodium phosphate buffer (0.05 M, pH 4.0) and methanol (33:67, v/v). Atorvastatin and the internal standard were detected by ultraviolet absorbance at 247 nm. The average recoveries of the drug and internal standard were 95 and 80%, respectively. The lower limits of detection and quantification were I and 4 ng/ml, respectively, and the calibration curves were linear over a concentration range of 4-256 ng/ml of atorvastatin in human serum. The analysis performance was studied and the method was applied in a randomized cross-over bioequivalence study of two different atorvastatin preparations in 12 healthy volunteers. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 45
页数:5
相关论文
共 26 条
[1]
Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection [J].
Al-Rawithi, S ;
Hussein, RF ;
Alzahrani, A .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :88-92
[2]
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia [J].
BakkerArkema, RG ;
Davidson, MH ;
Goldstein, RJ ;
Davignon, J ;
Isaacsohn, JL ;
Weiss, SR ;
Keilson, LM ;
Brown, WV ;
Miller, VT ;
Shurzinske, LJ ;
Black, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :128-133
[3]
Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma [J].
Bullen, WW ;
Miller, RA ;
Hayes, RN .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 1999, 10 (01) :55-66
[4]
HIGHLY SENSITIVE AND SPECIFIC DETERMINATION OF PRAVASTATIN SODIUM IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH LASER-INDUCED FLUORESCENCE DETECTION AFTER IMMOBILIZED ANTIBODY EXTRACTION [J].
DUMOUSSEAUX, C ;
MURAMATSU, S ;
TAKASAKI, W ;
TAKAHAGI, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (11) :1630-1636
[5]
Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples [J].
Ertürk, S ;
Önal, A ;
Çetin, SM .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 793 (02) :193-205
[6]
Hayes R., 1996, Pharmaceutical Research (New York), V13, pS47
[7]
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY DETERMINATION OF PRAVASTATIN IN PLASMA [J].
IACONA, I ;
REGAZZI, MB ;
BUGGIA, I ;
VILLANI, P ;
FIORITO, V ;
MOLINARO, M ;
GUARNONE, E .
THERAPEUTIC DRUG MONITORING, 1994, 16 (02) :191-195
[8]
Jemal M, 1999, RAPID COMMUN MASS SP, V13, P1003, DOI 10.1002/(SICI)1097-0231(19990615)13:11<1003::AID-RCM597>3.0.CO
[9]
2-L
[10]
Quantitative determination of pravastatin and R-416, its main metabolite in human plasma, by liquid chromatography-tandem mass spectrometry [J].
Kawabata, K ;
Samata, N ;
Urasaki, Y .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 816 (1-2) :73-79